Can BTK inhibitors finally move the needle in progressive MS? Dr Robert Fox joins Dr Anne Cross to unpack the results of the HERCULES trial and explore what's next.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002605. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. 

Resources

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/40202696/

Bruton Tyrosine Kinase Inhibitors in Multiple Sclerosis: Evidence and Expectations https://pubmed.ncbi.nlm.nih.gov/38533819/

Safety and Efficacy of Tolebrutinib, an Oral Brain-Penetrant BTK Inhibitor, in Relapsing Multiple Sclerosis: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/34418400/

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis https://clinicaltrials.gov/study/NCT03996291

Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/40202623/

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS) https://clinicaltrials.gov/study/NCT04458051

Fenebrutinib, a Bruton's Tyrosine Kinase Inhibitor, Blocks Distinct Human Microglial Signaling Pathways https://pubmed.ncbi.nlm.nih.gov/39465429/

Rilzabrutinib, a Reversible Covalent Bruton's Tyrosine Kinase Inhibitor: Absorption, Metabolism, Excretion, and Absolute Bioavailability in Healthy Participants https://pubmed.ncbi.nlm.nih.gov/37060187/

Orelabrutinib: First Approval https://pubmed.ncbi.nlm.nih.gov/33704654/

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/38648580/

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/30157388/